CANDEL THERAPEUTICS, INC. Prepaid Expense and Other Assets, Current
CANDEL THERAPEUTICS, INC. (CADL) had Prepaid Expense and Other Assets, Current of $2.59 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-13
- 2026-06-30: Prepaid Expense and Other Assets, Current $2.59M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $2.92M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $1.66M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $3.17M.
| Period end | Prepaid Expense and Other Assets, Current |
|---|---|
| 2026-06-30 | $2.59M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $2.92M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $1.66M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $3.17M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.92M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $983.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $1.15M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.53M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.28M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.42M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $1.38M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.12M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.47M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $2.62M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.89M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.89M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $544.00K 10-Q · filed 2022-08-05 |
| 2022-03-31 | $1.32M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.30M 10-K · filed 2023-03-30 |
| 2021-09-30 | $2.56M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $110.00K 10-Q · filed 2021-09-08 |
| 2020-12-31 | $93.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |